NON-HUMAN PRIMATE MODELS FOR EVALUATION OF AIDS THERAPIE

合同的主要活动将是评估（i）治疗 方法和（ii）单独的粘膜传递抑制剂和 组合.术语“治疗方法”包括但不限于： 限于以下：抗病毒剂（药物和生物制剂）， 免疫策略和基因疗法。术语“传输” 抑制剂”包括基于药物、基于免疫、生物制剂和天然药物。 性传播的抑制剂。从这些研究中排除 是预防性的基于疫苗的病毒传播抑制。 评价包括确定疗效和毒性， 需要时，药代动力学有限。模型开发将继续进行 作为这个项目的一个组成部分， 现有的模型。

The primary activity of the contract will be to evaluate (i) therapeutic approaches and (ii) inhibitors of mucosal transmission alone and in combination. The term "therapeutic approaches" includes, but is not limited to, the following: antiviral agents (drugs and biologics), immune-based strategies, and gene-based therapy. The term "transmission inhibitor" includes drug-based, immune-based, biologics, and natural product inhibitors of sexual transmission. Excluded from these studies is prophylactic vaccine-based suppression of viral transmission. Evaluation encompasses the determination of efficacy and toxicity and when needed, limited pharmacokinetics. Model development will continue to be an integral part of this program only with respect to improving existing models.